A serological survey and risk factor study was conducted to estimate the prevalence of Eperythrozoon ovis infection in Western Australian weaner sheep, the prevalence of farms with infected sheep, and to identify factors affecting initiation and maintenance of infection on the farm. The study was conducted on 91 farms, purposively chosen from 41 randomly selected regional shires stratified by sheep number and rainfall zones. Twenty sheep were selected systematically from a mixed-sex flock on each farm and tested for serum antibody to E ovis using an enzyme-linked immunosorbent assay. Information on putative risk factors was collected using an interview questionnaire. Antibody to E ovis was detected in 4.5% of sheep on 47% of the farms sampled. The prevalence of E ovis infection in sheep was estimated at the 95% confidence level to be between 3.6 and 5.5%, and the prevalence of farms with infected sheep was estimated to be between 37.5 and 56.5%. Most farms with serological evidence of infection occurred in the Great Southern agricultural region (79.5%), south-east of Perth through to Albany (latitude 32 to 34 degrees S, longitude 116 to 120 degrees E), and in the Northern region (12.8%) surrounding Geraldton (latitude 29 degrees S, longitude 114 degrees E). There were significantly more farms (P less than 0.05) with evidence of infection in the Great Southern region compared to the Central region between Geraldton and Perth, and on farms in the region south compared to north of latitude 32 degrees S. None of the putative risk factors examined in the questionnaire were associated with serological evidence of infection on the farm.(ABSTRACT TRUNCATED AT 250 WORDS)

Two vaccines, based on formalin-killed whole cells of toxigenic Pasteurella multocida type D and Bordetella bronchiseptica combined with a partially toxoided cell extract of P multocida, were prepared with Freund's incomplete adjuvant (vaccine 1) or by alum precipitation (vaccine 2). Each was tested for safety and efficacy in reducing the severity of nasal turbinate atrophy and improving the growth rate of pigs in three Western Australian commercial piggeries with endemic atrophic rhinitis. In safety experiments with vaccine 1, no adverse clinical effects were observed in vaccinated sows or their progeny. Piglets receiving vaccine 2 showed no injection site abnormalities, pyrexia or turbinate atrophy. In field trials, vaccine 1 significantly reduced the prevalence of moderate to severe nasal turbinate atrophy (Done score 3 to 5) when used in two piggeries (A and B). Progeny from vaccinated sows in piggery B also grew significantly faster than controls. When vaccine 2 was used in piggery A at a later date and in another piggery (C), growth rate was not improved in either piggery and the prevalence of moderate to severe turbinate atrophy was reduced only in piggery C.

No abstract

No abstract

No abstract